ECSP066752A - Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida - Google Patents

Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida

Info

Publication number
ECSP066752A
ECSP066752A EC2006006752A ECSP066752A ECSP066752A EC SP066752 A ECSP066752 A EC SP066752A EC 2006006752 A EC2006006752 A EC 2006006752A EC SP066752 A ECSP066752 A EC SP066752A EC SP066752 A ECSP066752 A EC SP066752A
Authority
EC
Ecuador
Prior art keywords
salt
methyl
phenyl
tartrate
ilmetile
Prior art date
Application number
EC2006006752A
Other languages
English (en)
Inventor
Paul William Manley
Michael Mutz
Hans Michael Buerger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066752(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP066752A publication Critical patent/ECSP066752A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a las sales de adición de ácido de 4-[4-metil-1-piperazinilmetil]-N-[4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]fenil]-benzamida, que se seleccionan del grupo que consiste de una sal de tartrato, tal como una sal de (D)(-)tartrato o sal de (L)(+) tartrato, sal de clorhidrato, sal de citrato, sal de malato, sal de fumarato, sal de succinato, sal de benzoato, sal de bencensulfonato, sal de pamoato, sal de formiato, sal de malonato, sal de 1,5-naftalendisulfonato, sal de silicato, sal de ciclohexansulfamiato, sal de lactato, sal de mandelato, sal de glutarato acuosa, sal de adipato, sal de escuarato, sal de vanilato, sal de oxaloacetato, sal de ascorbato, y sal de sulfato.
EC2006006752A 2004-02-04 2006-08-03 Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida ECSP066752A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54181704P 2004-02-04 2004-02-04

Publications (1)

Publication Number Publication Date
ECSP066752A true ECSP066752A (es) 2006-11-16

Family

ID=34837520

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006752A ECSP066752A (es) 2004-02-04 2006-08-03 Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida

Country Status (22)

Country Link
US (3) US20080249104A1 (es)
EP (1) EP1713792B1 (es)
JP (1) JP4937760B2 (es)
KR (2) KR20120127525A (es)
CN (1) CN100558723C (es)
AR (1) AR047530A1 (es)
AU (1) AU2005211514B2 (es)
BR (1) BRPI0507464A (es)
CA (1) CA2553887C (es)
EC (1) ECSP066752A (es)
IL (1) IL177005A (es)
MA (1) MA28428B1 (es)
MY (1) MY144177A (es)
NO (1) NO20063942L (es)
NZ (1) NZ548714A (es)
PE (1) PE20051096A1 (es)
PH (1) PH12013500157A1 (es)
RU (1) RU2375355C2 (es)
TN (1) TNSN06243A1 (es)
TW (1) TWI347186B (es)
WO (1) WO2005075454A2 (es)
ZA (1) ZA200605972B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CN102351842B (zh) 2005-11-25 2014-07-23 诺华股份有限公司 甲磺酸伊马替尼的f、g、h、i 和k晶形
KR100799821B1 (ko) * 2007-02-05 2008-01-31 동화약품공업주식회사 신규한 이마티닙 캠실레이트 및 그의 제조방법
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
JP2010540465A (ja) 2007-09-25 2010-12-24 テバ ファーマシューティカル インダストリーズ リミティド 安定なイマチニブ組成物
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
CN110818633A (zh) 2009-01-16 2020-02-21 埃克塞里艾克西斯公司 一种苹果酸盐及其晶型
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
HRP20171415T4 (hr) * 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
CA2775400A1 (en) 2009-09-28 2011-03-31 Medizinische Universitat Wien New use of pdgfrbeta inhibitors
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
KR101138840B1 (ko) * 2009-12-28 2012-05-10 주식회사 셀트리온화학연구소 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
WO2011114337A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
EP2582689B1 (en) 2010-06-18 2017-03-01 KRKA, D.D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
AU2013245008B2 (en) 2012-04-04 2017-03-30 Intervet International B.V. Soft chewable pharmaceutical products
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
EP3027026A4 (en) 2013-07-31 2017-05-03 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
EP3407874B1 (en) 2016-01-25 2024-05-22 KRKA, d.d., Novo mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP3691861B2 (ja) * 1994-09-14 2005-09-07 株式会社東芝 光ディスク用光パルス幅制御装置
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
DE60308337T2 (de) * 2002-03-15 2007-09-20 Novartis Ag 4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyrimidin-3-yl)pyrimidin-2-ylamino)phenylbenzamid zur Behandlung von Ang II vermitteltern Erkrankungen
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
CN102351842B (zh) * 2005-11-25 2014-07-23 诺华股份有限公司 甲磺酸伊马替尼的f、g、h、i 和k晶形

Also Published As

Publication number Publication date
ZA200605972B (en) 2007-11-28
US20140051853A1 (en) 2014-02-20
AU2005211514A1 (en) 2005-08-18
NZ548714A (en) 2009-08-28
CA2553887A1 (en) 2005-08-18
AR047530A1 (es) 2006-01-25
KR20060135735A (ko) 2006-12-29
MY144177A (en) 2011-08-15
NO20063942L (no) 2006-11-02
BRPI0507464A (pt) 2007-07-10
WO2005075454A3 (en) 2006-07-27
RU2375355C2 (ru) 2009-12-10
IL177005A (en) 2014-05-28
US20080249104A1 (en) 2008-10-09
US8513256B2 (en) 2013-08-20
MA28428B1 (fr) 2007-02-01
TNSN06243A1 (en) 2007-12-03
WO2005075454A2 (en) 2005-08-18
US20120142697A1 (en) 2012-06-07
EP1713792B1 (en) 2014-04-30
JP2007520518A (ja) 2007-07-26
EP1713792A2 (en) 2006-10-25
RU2006131548A (ru) 2008-03-10
CN1914191A (zh) 2007-02-14
IL177005A0 (en) 2006-12-10
TWI347186B (en) 2011-08-21
TW200529854A (en) 2005-09-16
PH12013500157A1 (en) 2014-09-08
CN100558723C (zh) 2009-11-11
JP4937760B2 (ja) 2012-05-23
PE20051096A1 (es) 2006-01-23
CA2553887C (en) 2013-04-16
AU2005211514B2 (en) 2009-09-10
KR20120127525A (ko) 2012-11-21

Similar Documents

Publication Publication Date Title
ECSP066752A (es) Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
WO2005095379A3 (en) Crystalline methanesulfonic acid addition salts of imatinib
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
NZ599343A (en) Substituted piperidines that increase p53 activity and the uses thereof
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
NO20081581L (no) Polymorfer av benzoatsalt av 2-[[6-[(3R)-3-amino-l-piperldinyl]-3,4-dihydro-3-metyl-2,4-diokso- 1(2H)-pyrlmidinylJmetyl)benzonitril, og fremgangsmater for anvendelse derav
RU2009149216A (ru) Бициклические амиды как ингибиторы киназы
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
AR053984A1 (es) Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas
HK1087638A1 (en) Use of tyrosine kinase inhibitors to treat diabetes
BR112023004656A2 (pt) Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
ATE451367T1 (de) Verfahren zur herstellung von ziprasidon
DE602005025514D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms
TH74677A (th) รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด
AR079196A1 (es) Formas solidas de la 4-((r)-(3-aminofenil) (4-(4- fluorobencil) piperazin -1-il) metil)-n,n-dietilbenzamida, sus composiciones y usos
TH74677B (th) รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
AR055284A1 (es) R-enantiomeros de n- propargil- 1- aminoindano, sales, composiciones y usos de los mismos
ATE480534T1 (de) Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz
PL366885A1 (en) Method for manufacturing crystalline form alpha of additive salt of metanesulphonic acid and 4-(4-methylpiperazin-1-yl methyl)-n-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl amine] phenyl] benzamide